Latvia

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: Latvia's pharmaceutical market expanded strongly in the first half of 2011 but weaker growth towards the end of the year, combined with ongoing concerns over the external... 2012-03-16

BMI View: Despite a contraction in pharmaceutical prices, Latvia's pharmaceutical market has performed strongly in first nine months of 2011, which has led to upward revisions in our... 2011-11-14

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: Latvia's disease profile and relatively low per-capita consumption of pharmaceuticals (compared with the rest of developed Europe) is a clear illustration of the need for... 2011-06-07

BMI View: Our view that Latvia will return only weak pharmaceutical market growth in 2011 remains firmly in play. The performance of this market remains indelibly tied to the country's... 2011-05-17

BMI View: The economies of Lithuania, Estonia and Latvia were among the worst hit in Europe during the global economic crisis of 2007-2010 and the region's drug markets have not been... 2011-03-08